Ignite Creation Date:
2024-05-05 @ 12:01 PM
Last Modification Date:
2024-10-26 @ 9:19 AM
Study NCT ID:
NCT00216398
Status:
COMPLETED
Last Update Posted:
2019-08-16
First Post:
2005-09-13
Brief Title:
Lanreotide Autogel in Patients With Acromegaly Previously Treated With Octreotide LAR
Sponsor:
Ipsen
Organization:
Ipsen
Study Overview
Official Title:
A Phase IV Open-label Single Group Study to Evaluate the Dosing Efficacy and Safety of Lanreotide Autogel in Patients With Acromegaly Previously Treated With Octreotide LAR
Status:
COMPLETED
Status Verified Date:
2019-08
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to assess the efficacy safety and patient acceptability of Somatuline Autogel in patients with acromegaly previously treated with octreotide LAR
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None